Overproduction, Purification, and Stability of the Functionally Active Human Carnitine Acetyl Transferase
-
Published:2022-06-21
Issue:12
Volume:64
Page:1431-1440
-
ISSN:1073-6085
-
Container-title:Molecular Biotechnology
-
language:en
-
Short-container-title:Mol Biotechnol
Author:
Giudice Deborah, Console Lara, Arduini Arduino, Indiveri CesareORCID
Abstract
AbstractHuman Carnitine Acetyl Transferase (hCAT) reversibly catalyzes the transfer of the acetyl-moiety from acetyl-CoA to L-carnitine, modulating the acetyl-CoA/CoA ratio in mitochondria. Derangement of acetyl-CoA/CoA ratio leads to metabolic alterations that could result in the onset or worsening of pathological states. Due to the importance of CAT as a pharmacological target and to the European directive for reducing animal experimentation, we have pointed out a procedure to produce a recombinant, pure, and functional hCAT using the E. coli expression system. The cDNA encoding for the hCAT was cloned into the pH6EX3 vector. This construct was used to transform the E. coli Rosetta strain. The optimal conditions for the overexpression of the fully active hCAT include induction with a low concentration of IPTG (0.01 mM) and a low growth temperature (25 °C). The recombinant protein was purified from bacterial homogenate by affinity chromatography. The pure hCAT is very stable in an aqueous solution, retaining full activity for at least two months if stored at − 20 °C. These results could be helpful for a broad set of functional studies on hCAT, including drug-design applications.
Funder
Ministero dell’Istruzione, dell’Università e della Ricerca Università della Calabria
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology
Reference23 articles.
1. Govindasamy, L., Kukar, T., Lian, W., Pedersen, B., Gu, Y., Agbandje-McKenna, M., Jin, S., McKenna, R., & Wu, D. (2004). Structural and mutational characterization of L-carnitine binding to human carnitine acetyltransferase. Journal of Structural Biology, 146, 416–424. 2. Arduini, A., Bonomini, M., Savica, V., Amato, A., & Zammit, V. (2008). Carnitine in metabolic disease: Potential for pharmacological intervention. Pharmacology & Therapeutics, 120, 149–156. 3. Abdel-aleem, S., Sayed-Ahmed, M., Nada, M. A., Hendrickson, S. C., St Louis, J., & Lowe, J. E. (1995). Stimulation of non-oxidative glucose utilization by L-carnitine in isolated myocytes. Journal of Molecular and Cellular Cardiology, 27, 2465–2472. 4. Heo, H. J., Suh, Y. M., Kim, M. J., Choi, S. J., Mun, N. S., Kim, H. K., Kim, E., Kim, C. J., Cho, H. Y., Kim, Y. J., & Shin, D. H. (2006). Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia. Bioscience, Biotechnology, and Biochemistry, 70, 107–111. 5. Zammit, V. A., Ramsay, R. R., Bonomini, M., & Arduini, A. (2009). Carnitine, mitochondrial function and therapy. Advanced Drug Delivery Reviews, 61, 1353–1362.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|